worldwide distribution deal signed, page-16

The product seems unique but effective in its field. It seems easy to use (which is a must in this field) while giving data that will alter best practice for treatment.

In terms of total costs of patient management its nothing too great as you only need to be assessed once, or probably once every 6 months (as they do in convential sleep labs atm).

So its a cheap convenient way of getting extra information about a patient's condition. It will be used on patients who are willing to spend money on their conditions (not just geriatrics) and its been approved by the major insurance companies as a valid, rebatable technique.

If this goes mainstream in western medicine as a boutique item for severe childhood asthma sufferers, and each device 'sold' 'rented' or otherwise makes approx 30k Per annum, this company is worth a lot more than 10 million.

That is my take on this atm

I dont know the exact business model to sell or rent devices or whatever, but I think we'll hear more when we know the specifics of the distribution deal?

Or maybe I just need to read more anns.